Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Merkel cell carcinoma
anti-programmed death ligand 1 inhibitor
avelumab
immune checkpoint inhibitor
thyroid transcription factor 1
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
07
06
2020
accepted:
14
07
2020
pubmed:
15
8
2020
medline:
15
5
2021
entrez:
15
8
2020
Statut:
ppublish
Résumé
Merkel cell carcinoma (MCC) is an aggressive neoplasm and patients with metastasis have poor survival outcomes. Recently, avelumab, an anti-programmed death ligand 1 (PD-L1) immune checkpoint inhibitor, was approved for first-line treatment in patients with metastatic MCC. While the administration interval of avelumab is every 2 weeks, the durable effect of a single administration of avelumab is unknown. Additionally, the effect of avelumab in pure MCC or combined MCC concurrent with non-MCC histology has not been fully elucidated. Herein, we report a case of combined MCC concurrent with squamous cell carcinoma; the patient had a complete response after a single administration of avelumab. Although the levels of avelumab were outside the detection limit within 12 weeks, a remarkable efficacy remained for more than 28 weeks after administration. Immunohistochemical analyses revealed that the expression of PD-L1 and Merkel cell polyomavirus large T antigen was almost negative or only partial in the primary tumor lesion of this patient. Conversely, thyroid transcription factor 1 (TTF-1) expression was positive in the primary MCC lesion, which is consistent with a previous report that combined MCC is positive for TTF-1 expression. In conclusion, this case study presents a rare case of TTF-1-positive combined MCC showing complete response after a single administration of avelumab.
Identifiants
pubmed: 32794263
doi: 10.1111/1346-8138.15543
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Thyroid Nuclear Factor 1
0
avelumab
KXG2PJ551I
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1317-1321Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K21328
Organisme : Japan Society for the Promotion of Science
ID : 20K17353
Informations de copyright
© 2020 Japanese Dermatological Association.
Références
Lebbe C, Becker JC, Grob JJ et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Euro J Cancer 2015; 51: 2396-2403.
Kaufman HL, Russell JS, Hamid O et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018; 6: 7.
Nghiem P, Kaufman HL, Bharmal M et al. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol 2017; 13: 1263-1279.
Kaufman HL, Russell J, Hamid O et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374-1385.
D'Angelo SP, Russell J, Lebbe C et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol 2018; 4: e180077.
Czapiewski P, Majewska H, Kutzner H et al. TTF-1 and PAX5 are frequently expressed in combined Merkel cell carcinoma. Am J Dermatopathol 2016; 38: 513-516.
Narisawa Y, Koba S, Inoue T et al. Histogenesis of pure and combined Merkel cell carcinomas: an immunohistochemical study of 14 cases. J Dermatol 2015; 42: 445-452.
Kuwamoto S. Recent advances in the biology of Merkel cell carcinoma. Hum Pathol 2011; 42: 1063-1077.
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Euro J Cancer 2009; 45: 228-247.
Feng H, Shuda M, Chang Y et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-1100.
Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 2012; 7: 123-144.
Miller NJ, Church CD, Fling SP et al. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. J Immunother Cancer 2018; 6: 131.
Chou TC, Tsai KB, Wu CY et al. Presence of the Merkel cell polyomavirus in Merkel cell carcinoma combined with squamous cell carcinoma in a patient with chronic arsenism. Clin Exp Dermatol 2016; 41: 902-905.
Iwasaki T, Matsushita M, Kuwamoto S et al. Usefulness of significant morphologic characteristics in distinguishing between Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative Merkel cell carcinomas. Hum Pathol 2013; 44: 1912-1917.
Kretz-Rommel A, Qin F, Dakappagari N et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007; 178: 5595-5605.